New Rapid-acting Antidepressants

This book discusses new candidates for rapid-acting antidepressants, such as (R)-ketamine, (2R,6R)-hydroxynorketamine, scopolamine, mGluR2/3 antagonists and AMPA receptor agonists. There are serious limitations to currently available antidepressants, such as delayed onset and low rates of efficacy. The discovery that a single dose of ketamine, an NMDAR antagonist, can produce rapid antidepressant effects that are sustained has led to new research in this area. In this volume, a variety of novel pharmaceutical treatments are examined. This volume would be useful to both researchers and clinicians who work in the field of pharmacology, specifically CNS drug treatments. Preface Contents (R)-Ketamine: A New Rapid-Acting Antidepressant • Kai Zhang and Kenji Hashimoto (2R,6R)-Hydroxynorketamine, A Metabolite of Ketamine: The Antidepressant Actions and the Mechanisms • Kenichi Fukumoto and Ronald S. Duman Predictable Biomarkers for Rapid-Acting Antidepressant Response to Ketamine • Yunfei Tan and Kenji Hashimoto Nitrous Oxide: An Old Compound with Emerging Psychotropic Properties • Lojine Y. Kamel, Darin F. Quach, Britt M. Gott, and Charles R. Conway Novel AMPA Receptor Potentiators TAK-137 and TAK-653 as Potential Rapid-Acting Antidepressants • Haruhide Kimura AMPA Receptor Potentiators as Potential Rapid-Acting Antidepressants • Emilio Garro-Martínez and Albert Adell mGlu2/3 Receptor Antagonists as Rapid-Acting Antidepressants • Shigeyuki Chaki Antidepressant Effects of the Muscarinic Receptor Antagonist Scopolamine: Clinical and Preclinical Review • Maura L. Furey, Wayne C. Drevets, and Anindya Bhattacharya Index